中新经纬12月24日电 (林琬斯)近日,手握“流感神药”磷酸奥司他韦(商品名可威)的广东东阳光药业股份有限公司(下称东阳光药)向港交所递交上市申请。每到流感季,流感用药需求量大幅增长,磷酸奥司他韦便会被推向风口。2023年,可威销售额55亿元,营收占比超七成,市占超60%。不过,2024年上半年,可威销售减少,东阳光药收入随之下滑。“流感神药”卖55亿元招股书显示,东阳光药成立于2003年,主要...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.